AB1313

SYSTEMATIC SCREENING OF COMORBIDITIES IN CHRONIC INFLAMMATORY RHEUMATIC DISEASES IN DAILY PRACTICE: A RETROSPECTIVE MONOCENTRIC FRENCH STUDY ACCORDING TO RECENT EULAR GUIDELINES

J. Hubac1, R. Gastaïdi2, B. Allenet2, P. Gaudin1, A. Baillet1. Rheumatology, Pharmacy, CHU Grenoble Alpes, grenoble, France

Background: In chronic inflammatory rheumatic diseases, comorbidities such as cardiovascular diseases and infections are more frequently observed than in general population and are suboptimally prevented, screened and managed.1,3,4 A nurse-led programme demonstrated the short-term benefit on management of comorbidities in rheumatoid arthritis patients.5 EULAR recently published points to consider for reporting, screening, and preventing specific comorbidities in chronic inflammatory rheumatic diseases in daily practice.

Objectives: Our objective was to screen and report comorbidities in chronic inflammatory rheumatic diseases patients in daily practice according to recent EULAR guidelines.

Methods: We included patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis from November 2016 to November 2017 in a retrospective monocentric study in the rheumatology department of the Grenoble Alpes Teaching Hospital. Data regarding comorbidities were collected in a standardised multi-disciplinary consultation with a rheumatologist, a specialised nurse and a hospital pharmacist according to EULAR and French Society of Rheumatology guidelines. Data concerning cardiovascular diseases, infectious comorbidities, cancer screening, and osteoporosis were collected. Data about the rheumatic disease including treatment and disease activity were recorded. Adherence was analysed in consultation by the pharmacist. Recommendations were notified to the patients, his general practitioner, and rheumatologist on a standardised list. Data were analysed as mean/SD if appropriate and percentage.

Results: We included 101 patients, 43 patients had rheumatoid arthritis, 45 had spondyloarthritides, and 13 were diagnosed with psoriatic arthritis. The mean age was 49.6 years old.14,5 50 patients were followed in the hospital, 39 were followed by private practitioners and 12 were followed by both. All patients were treated with bDMARDs. In average, patients received 2.3 (SD 1.6) different biologic treatments. In our total population, 55.5% had influenza vaccination >1 year ago, 42,6% had an appointment to the dermatologist >1 year ago, 25% of the women between 50 and 75 years old had a mammography >2 years ago and 27.3% of women>50 years old with FRAX above threshold were not treated for osteoporosis. Moreover, 60,5% of patients with rheumatoid arthritis had a Heart Score >1% and 45,6% in the total population.

Conclusions: Our monocentric study confirmed that comorbidities are frequent and suboptimally prevented and managed according to the EULAR point to consider. An evaluation of the efficiency of our standardised consultation and intervention is necessary.

REFERENCES:

Acknowledgements: M. Clay
Disclosure of Interest: None declared

AB1314

LACK OF ASSOCIATION BETWEEN ABO BLOOD GROUPS AND RHEUMATIC DISEASES IN CHINA: A SINGLE-CENTRE EXPERIENCE

J. Qi, Q. lv, Z. chen, X. Zhang, M. Yang, Y. Zhang, J. Gu. Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Background: Various genetic and environmental risk factors have been shown to be associated with the incidence of rheumatic diseases. Several studies have shown associations of ABO blood groups with various diseases.

Objectives: Our study aimed to determine whether there is an association between the types of rheumatic diseases and ABO blood groups.

Methods: The study included the patients, followed up at the Immunology-Rheumatology clinic between January 2010 and December 2017 for diagnosis of rheumatic disease, who had an ABO Rh blood data. Age, gender, type of rheumatic disease, ABO Rh blood groups were recorded.

Results: A total of 1551 patients were included in the study, such as 392 AS patients, 297 RA patients, 752 SLE patients and 110 pSS. The patients were assessed for blood types, 40,2% had O type, 26% patients had A type, 26.8% had B type, and 7.0% had AB type. AS, RA, SLE and pSS were more common in the patients with O blood type. The blood type where all the diseases are observed the least commonly was AB. There was no significant difference in the distribution of blood types in rheumatic diseases.

Conclusions: In our study, we thought that there was lack association between types of different rheumatic diseases and ABO blood groups.

REFERENCE:

Acknowledgements: None declared
Disclosure of Interest: None declared

AB1315

MEDICATION USE AMONG PREGNANT WOMEN WITH RHEUMATIC DISEASES IN KOREA BASED ON THE NATIONAL HEALTH INSURANCE SERVICE-NATIONAL SAMPLE COHORT

M.K. Chung1, J. Lee1, E.-H. Ha2, J.-Y. Shin3. 1Division of Rheumatology, Department of Internal Medicine, 2Department of Occupational and Environmental Medicine, Ewha Womans University School of Medicine, Seoul, Korea, Republic of Ireland

Background: Many rheumatic diseases (RD) predominantly affect women in their reproductive ages. Medication use during pregnancy is an important issue in women with RD since it may affect the health of both fetus and the mother.

Objectives: This study aimed to characterise the status of medication dispensed for Korean women with RD in pre-gestational period and during pregnancy.

Methods: Women aged between 20–44 years and diagnosed as RD and had delivery after the diagnosis of RD were identified from National Health Insurance Service-National Sample Cohort (NHIC-NSC) (2009–2013). Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and ankylosing spondylitis (AS) were included as RD. We analysed prevalence of RD related medication including disease-modifying antirheumatic drugs (DMARDs), NSAIDs, and corticosteroids (CSs) dispensed between the pre-gestational periods of 3 months before pregnancy until delivery. We also analysed prevalence of other medications and supplements which are commonly dispensed during pregnancy in women with RD and the age and sex matched controls.

Results: There were 71 deliveries among 1059 women with RD. In RD pregnancies, 54.9% had taken at least 1 RD related medications. The prevalence of DMARDs dispensing during pregnancy was 23.9%, CSs 43.7%, and NSAIDs 38.0% in RD population. Although usage of antibiotics and medication for thyroid diseases during pregnancies were not different between the women with RD and the control, use of vitamin and iron supplements were significantly higher in the women with RD (38.0% vs 13.4%, p<0.0001).